Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Aytu Biopharma Inc (AYTU)

Aytu Biopharma Inc (AYTU)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 9,163
  • Shares Outstanding, K 6,149
  • Annual Sales, $ 81,000 K
  • Annual Income, $ -15,840 K
  • EBIT $ 0 M
  • EBITDA $ 9 M
  • 60-Month Beta -1.40
  • Price/Sales 0.12
  • Price/Cash Flow N/A
  • Price/Book 0.33

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/23
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year -1.20
  • Growth Rate Est. (year over year) +83,350.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.4100 +5.67%
on 11/18/24
2.3000 -35.22%
on 10/21/24
-0.8000 (-34.93%)
since 10/18/24
3-Month
1.4100 +5.67%
on 11/18/24
2.8500 -47.72%
on 09/26/24
-1.2600 (-45.82%)
since 08/20/24
52-Week
1.4100 +5.67%
on 11/18/24
3.4500 -56.81%
on 02/15/24
-0.9100 (-37.92%)
since 11/20/23

Most Recent Stories

More News
Alaska Air clears a big hurdle in its proposed merger with Hawaiian Airlines

Alaska Air is one step closer to acquiring Hawaiian Airlines after the U.S. Department of Justice chose not to challenge the $1.9 billion deal that the carriers say will create a company better able to...

MIRA : 1.2800 (+1.19%)
NTGR : 24.10 (-0.29%)
AYTU : 1.4900 (-6.59%)
$SPX : 5,917.11 (unch)
$DOWI : 43,408.47 (+0.32%)
$IUXX : 20,667.10 (-0.08%)
Aytu BioPharma to Participate in the Canaccord Genuity 42nd Annual Growth Conference

ENGLEWOOD, CO / ACCESSWIRE / July 26, 2022 / Aytu BioPharma, Inc. (the "Company") (NASDAQ:AYTU), a pharmaceutical company focused on developing and commercializing novel therapeutics, today announced that...

AYTU : 1.4900 (-6.59%)
Aytu BioPharma Announces Initiation of the AR101 PREVEnt Trial for the Treatment of Vascular Ehlers-Danlos Syndrome

ENGLEWOOD, CO / ACCESSWIRE / July 20, 2022 / Aytu BioPharma, Inc. (NASDAQ:AYTU), a pharmaceutical company focused on developing and commercializing novel therapeutics, today announced the initiation of...

AYTU : 1.4900 (-6.59%)
Aytu BioPharma Announces the Appointment of Vivian Liu to the Company's Board of Directors

ENGLEWOOD, CO / ACCESSWIRE / June 29, 2022 / Aytu BioPharma, Inc. (NASDAQ:AYTU), a pharmaceutical company focused on developing and commercializing novel therapeutics, today announced the appointment of...

AYTU : 1.4900 (-6.59%)
Aytu BioPharma to Participate in the Lytham Partners Summer 2022 Investor Conference

ENGLEWOOD, CO / ACCESSWIRE / June 13, 2022 / Aytu BioPharma, Inc. (NASDAQ:AYTU), a pharmaceutical company focused on developing and commercializing novel therapeutics, today announced that the company...

AYTU : 1.4900 (-6.59%)
Aytu BioPharma Reports Third Quarter 2022 Financial Results and Outlines Key Strategic Priorities

Quarterly Net Revenue Increased 79% Year-Over-Year to $24.2 Million, the Highest Revenue in Company History Strategic Priorities Focused on Driving Revenue Growth, Increasing Financial Efficiencies and...

AYTU : 1.4900 (-6.59%)
Aytu BioPharma Announces Positive Preclinical Data in Ventilator-Associated Pneumonia with its Novel, Proprietary Healight(TM) Delivery Technology

Preclinical Proof-of-Concept Study Demonstrates Effectiveness of Healight in Delaying Time to Development of Ventilator-Associated Pneumonia ENGLEWOOD, CO / ACCESSWIRE / April 25, 2022 / Aytu BioPharma,...

AYTU : 1.4900 (-6.59%)
Aytu BioPharma Announces Fast Track Designation Granted to AR101 for the Treatment of Vascular Ehlers-Danlos Syndrome

ENGLEWOOD, CO / ACCESSWIRE / April 19, 2022 / Aytu BioPharma, Inc. (NASDAQ:AYTU), a pharmaceutical company focused on developing and commercializing novel therapeutics, today announced that the U.S. Food...

AYTU : 1.4900 (-6.59%)
Aytu BioPharma Announces FDA Orange Book Listing of Newly Issued Patent for Cotempla XR-ODT(R)

ENGLEWOOD, CO / ACCESSWIRE / March 23, 2022 / Aytu BioPharma, Inc. (NASDAQ:AYTU), a pharmaceutical company focused on developing and commercializing novel therapeutics, today announced that its newly issued...

AYTU : 1.4900 (-6.59%)
Aytu BioPharma to Participate in the Cantor Fitzgerald Virtual Rare Orphan Disease Summit

ENGLEWOOD, CO / ACCESSWIRE / March 22, 2022 / Aytu BioPharma, Inc. (NASDAQ:AYTU), a pharmaceutical company focused on developing and commercializing novel therapeutics, today announced that management...

AYTU : 1.4900 (-6.59%)

Business Summary

Aytu BioScience, Inc. is a healthcare company which focused on commercialization of novel products in the field of urology. The company's marketed products consists of ProstaScint(R), Primsol(R) and MiOXSYS(TM) which addresses prostate cancer, urinary tract infections, male infertility and male sexual...

See More

Key Turning Points

3rd Resistance Point 1.6967
2nd Resistance Point 1.6393
1st Resistance Point 1.5647
Last Price 1.4900
1st Support Level 1.4327
2nd Support Level 1.3753
3rd Support Level 1.3007

See More

52-Week High 3.4500
Fibonacci 61.8% 2.6707
Fibonacci 50% 2.4300
Fibonacci 38.2% 2.1893
Last Price 1.4900
52-Week Low 1.4100

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar